Dr. Tomer Berkovitz is a General Partner at aMoon, where he co-leads aMoon’s Growth Fund. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.
Tomer places his relationship with our portfolio companies’ CEOs and founders as his top priority, partnering with entrepreneurs to enhance the value and growth of their company. Since joining aMoon in early 2018, Tomer has led the $55M Series D round of Seer (NASDAQ: SEER) and supported the company through additional private financing, spin-off and successful IPO. Tomer also led the $55M Series B of PrognomIQ and the $30M Series C round of Zebra Medical Vision, serving as a board member in both companies. Tomer also led SOPHiA GENETICS’ $110M Series F round and serves as the Chairman of its Strategy Committee.
Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he was promoted to Executive Director in record time. In this role, he led numerous capital market and mergers and acquisitions transactions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra, a NASDAQ listed biopharmaceutical company, where he led public equity offerings and its merger with Arcturus Therapeutics. Tomer earned his Ph.D. in Finance (with Distinction) from Columbia Business School.